Stock fact sheet · data as of
Krystal Biotech, Inc. (KRYS): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · High Growth
Is KRYS undervalued?
At 330.00 (close of 16 Oct 2026), KRYS trades 12% over the GLS average fair value of 294.13. 4 of the 8 models land above the price and 4 below. A negative margin of safety costs Value points in the Wheel Score (7 of 25 here) - the models see no discount, which does not make the business a poor one, only the price a full one.
There is a wide gap between EPV (90.86) and GLS Growth (500.61). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files KRYS under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for KRYS
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 484.55 | +47% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 92.02 | -72% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 467.74 | +42% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 204.43 | -38% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 500.61 | +52% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 167.17 | -49% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 345.68 | +5% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 90.86 | -72% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 30.76 | -91% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 395.20 | +20% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Krystal Biotech, Inc. scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. On durability KRYS scores 5.0/10 on the GLS Moat - a middle reading; the Scorecard on the Quote page's Financials tab shows which ten-year lines are steady and which are not.
Returns on capital are high - ROIC 16.7%, ROE 16.8%, ROA 15.4% - with debt at 0.01 times equity and a free-cash-flow yield of 2.6%.
Krystal Biotech, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 14 Sep 2026.
| Piotroski F-score | 5 / 9 | ROIC | 16.7% |
|---|---|---|---|
| GLS Moat | 5.0 / 10 | ROE | 16.8% |
| Debt / equity | 0.01 | ROA | 15.4% |
| Free-cash-flow yield | 2.6% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 61: Fair
A Wheel Score of 61 puts Krystal Biotech, Inc. in the Fair band - below the 70 the Sunday Scan requires. Value 7/25, Health 11/20, Moat 8/15, Premium 20/20 and Stability 15/20; the weakest part is Value (7/25).
Implied volatility is 49% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 6,270 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 284k shares a day on a market cap of $9.8B, with a beta of 0.50 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 15 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 7 / 25 | -12% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 8 / 15 | moat 5.0/10 | |
| Premium | 20 / 20 | implied volatility 49% | |
| Stability | 15 / 20 | 284k shares/day, $9.8B cap, beta 0.50 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 2 Nov 2026 (before the open), 17 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Krystal Biotech, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| TWST Twist Bioscience Corporation | 148.16 | - | - | 45Weak | $9.8B |
| TXG 10x Genomics, Inc. | 73.10 | 19.50 | -275% | 38Weak | $9.5B |
| PCVX Vaxcyte, Inc. | 67.55 | - | - | 45Weak | $10.4B |
| IBRX ImmunityBio, Inc. | 10.00 | - | - | 45Weak | $10.6B |
| MDGL Madrigal Pharmaceuticals, Inc. | 459.81 | 2,351.92 | +80% | 45Weak | $10.6B |
| CAI Caris Life Sciences, Inc. | 31.76 | 18.13 | -75% | 48Weak | $9.0B |
| KYMR Kymera Therapeutics, Inc. | 108.14 | 0.2471 | -43656% | 40Weak | $8.9B |
| CYTK Cytokinetics, Incorporated | 63.92 | - | - | 45Weak | $8.9B |
| PTGX Protagonist Therapeutics, Inc. | 136.28 | 38.39 | -255% | 51Fair | $8.8B |
| BMRN BioMarin Pharmaceutical Inc. | 56.05 | 24.83 | -126% | 59Fair | $10.8B |
| AXSM Axsome Therapeutics, Inc. | 161.79 | - | - | 45Weak | $8.5B |
| TECH Bio-Techne Corporation | 72.50 | 19.15 | -279% | 62Fair | $11.4B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about KRYS
Is KRYS undervalued right now?
No: at 330.00 the stock trades 12% above the GLS average fair value of 294.13 (data as of 16 Oct 2026). The margin of safety is negative.
What is the Wheel Score of KRYS and what does it mean?
KRYS scores 61 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for KRYS?
294.13 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Krystal Biotech, Inc. report earnings next?
The next earnings report is due on 2 Nov 2026 (before the open), 17 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does KRYS have listed options, and how liquid are they?
Yes. The nightly snapshot found 542 listed contracts with 6,270 open interest across all expiries and implied volatility of 49% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.